News & Updates
Stay informed about our latest developments and achievements
Cyron Therapeutics Signs $800M Technology Transfer Deal with Global Pharma Giant
Cyron Therapeutics has signed an exclusive licensing agreement with Novartis, a global Top 10 pharmaceutical company, for its innovative drug delivery...
AI-Powered Drug Discovery Platform Cuts Development Time by 50%
Cyron Therapeutics announced that its proprietary AI-based drug discovery platform 'CyronAI' has successfully reduced drug candidate discovery time by...
Rare Disease Treatment Receives FDA Orphan Drug Designation
Cyron Therapeutics' Duchenne Muscular Dystrophy (DMD) treatment candidate CYR-2001 has received Orphan Drug Designation from the U.S. Food and Drug Ad...
Korea's First CAR-T Cell Therapy Receives Clinical Trial Approval
Cyron Therapeutics' CAR-T cell therapy 'CYR-CAR01' has received approval from the Ministry of Food and Drug Safety for Phase 1/2 clinical trials, mark...
Cyron Therapeutics Secures $40M Series C Funding Round
Cyron Therapeutics has secured $40 million in Series C funding led by global healthcare investment firm OrbiMed. Existing investors SoftBank Ventures...
Cyron Therapeutics Signs Joint Research Agreement with Harvard Medical School
Cyron Therapeutics has signed a joint research agreement with the prestigious Harvard Medical School for brain disease treatment development. The agre...
Cyron Therapeutics Successfully Develops Next-Generation mRNA Vaccine Platform
Cyron Therapeutics has successfully developed a next-generation self-amplifying mRNA (saRNA) vaccine platform technology. This technology allows mRNA...
Research Published in Nature Medicine
A research paper on next-generation antibody-drug conjugate (ADC) technology by Cyron Therapeutics' research team has been published in the prestigiou...
Cyron CEO Invited as Keynote Speaker at BIO Asia
Cyron Therapeutics CEO has been invited as a keynote speaker at Asia's largest bio conference 'BIO Asia 2025' to be held in Tokyo this March. The CEO...